ProShares - Ultra Nasdaq Biotechnology
BIB
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- 7501 Wisconsin Avenue, Suite 1000E Bethesda MD United States of America 20814
- IPO Date
- Apr 9, 2010
- CIK
- 0001174610
- Website
- proshares.com
- Similar Companies
- Business
- ProShares Ultra Nasdaq Biotechnology (BIB) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index, a modified market-cap-weighted index measuring Nasdaq-listed biotechnology and pharmaceutical companies; it achieves this objective through investments in equity securities, derivatives such as total return swaps with counterparties including Citibank NA, BNP Paribas, Bank of America NA, Societe Generale, Goldman Sachs International, and UBS AG, U.S. Treasury obligations, and short-term investments. The fund offers leveraged exposure primarily to the health care sector, with top holdings including Vertex Pharmaceuticals Inc., Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals Inc., alongside approximately 250 other biotechnology and pharmaceutical stocks. BIB targets investors seeking amplified daily returns from the biotechnology industry segment, with options trading available and quarterly distributions. Launched on April 7, 2010, and managed by ProShare Advisors LLC under the ProShares Trust, the ETF is domiciled in the United States with net assets of approximately $44.3 million as of May 31, 2025, a net expense ratio of 0.95%, and a portfolio turnover rate of 28%. In a significant operational change, after the close of business on November 13, 2024, the fund's broad-based securities market index for comparative performance purposes shifted from the Nasdaq-100 Index to the Nasdaq Composite Index to provide a broader benchmark.